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Compelling evidence indicates that oxidative stress contributes to motor neuron injury in amyotrophic lateral
sclerosis (ALS), but antioxidant therapies have not yet achieved therapeutic beneﬁt in the clinic. The nuclear
erythroid 2-related-factor 2 (Nrf2) transcription factor is a key regulator of an important neuroprotective
response by driving the expression of multiple cytoprotective genes via its interaction with the antioxidant
response element (ARE). Dysregulation of the Nrf2-ARE system has been identiﬁed in ALS models and human
disease. Taking the Nrf2-ARE pathway as an attractive therapeutic target for neuroprotection in ALS, we aimed
to identify CNS penetrating, small molecule activators of Nrf2-mediated transcription in a library of 2000 drugs
and natural products. Compounds were screened extensively for Nrf2 activation, and antioxidant and
neuroprotective properties in vitro. S[+]-Apomorphine, a receptor-inactive enantiomer of the clinically
approved dopamine-receptor agonist (R[–]-apomorphine), was identiﬁed as a nontoxic Nrf2 activating
molecule. In vivo S[+]-apomorphine demonstrated CNS penetrance, Nrf2 induction, and signiﬁcant attenuation
of motor dysfunction in the SOD1G93A transgenic mouse model of ALS. S[+]-apomorphine also reduced
pathological oxidative stress and improved survival following an oxidative insult in ﬁbroblasts from ALS
patients. This molecule emerges as a promising candidate for evaluation as a potential neuroprotective agent in
ALS patients in the clinic.
& 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neurode-
generative disorder with rapid progression to death from neuro-
muscular respiratory failure in the majority of afﬂicted individuals.
Only one therapeutic agent, riluzole, has been shown to ameliorate
the disease course, with the modest effect of prolonging averager Inc.
ARE, antioxidant response
ihydroﬂuorescein diacetate;
n; MEFs, mouse embryonic
; PBPK, physiologically based
Shaw).
.
Open access under CC BY survival by approximately 3 months. There is an urgent need for
improved approaches to achieve neuroprotection in ALS.
Pathogenic mechanisms underlying ALS are not fully understood.
Evidence from model systems, and from ALS patients, provides strong
evidence for a role of oxidative stress in disease pathogenesis [1].
Oxidative stress has signiﬁcant crosstalk with other potential mechan-
isms of neuronal injury, including mitochondrial dysfunction [2],
excitotoxicity [3], protein aggregation [4], cytoskeletal dysfunction
[5], glial cell activation [6], and the entry of TDP43 into stress
granules [7,8]. It can feed into these mechanisms or be enhanced
by them. This central role in pathogenesis is reﬂected in a meta-
analysis of studies in the SOD1G93A transgenic mouse model of
ALS where therapies targeting oxidative stress have been high-
lighted as demonstrating the greatest promise in slowing disease
progression [9]. In ALS patients, there have been several trials of
antioxidant therapies, but these have universally suffered from
underpowered trial design or use of non-CNS penetrant or non-
drug-like molecules [10,11]. Interestingly, a prospective epidemio-
logical study of ∼1 million individuals showed that regular intake
of the antioxidant vitamin E reduced relative risk of subsequentlicense. 
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neuroprotective treatment for ALS, is an antiglutamatergic agent
which also has antioxidant properties [13].
Despite this central role, therapeutic targeting of oxidative
stress in ALS has failed to translate into clinical beneﬁt for patients.
This may be due in part to the lack of sufﬁciently potent
antioxidants able to penetrate the central nervous system (CNS)
[10]. An alternative novel approach for limiting oxidative stress in
neurodegenerative disease is to promote activation of the tran-
scription factor, NFE2-related factor 2 (Nrf2) [14,15].
Nrf2 is a Cap'n’Collar (CNC) basic region-leucine zipper (bZip)
transcription factor with a transactivation domain in the
N-terminal and a DNA binding region/leucine zipper structure in
the C-terminal end [16]. It is negatively regulated by an actin
binding cytosolic protein, Keap1 (Kelch-like ECH associated pro-
tein 1) [17], which acts as an adaptor and substrate binding
domain for a Cul3-based E3 ubiquitin ligase. This complex associ-
ates with NRF2 via a “hinge and latch mechanism” [18,19] where a
Keap1 homodimer binds two distinct motifs within the Neh2
domain of Nrf2, one of which forms a strong interaction (hinge)
and the second a weak interaction (latch). When the Keap1–Nrf2
complex is exposed to oxidative stress or small molecule electro-
philes, cysteine residues on Keap1 become oxidised, leading to
formation of intermolecular disulfhide bonds and a conforma-
tional change [20,21]. This leads to dissociation of the weak
interaction between Nrf2 and KEAP1, preventing ubiquitination
of Nrf2 and effectively blocking the Keap1-based E3 ubiquitin
ligase. Ultimately this increases net transfer of Nrf2 to the nucleus
where it can drive expression of antioxidant enzymes [19,22,23].
The Keap1–Nrf2 complex thus constitutes a cytoplasmic sensor for
oxidative stress and electrophilic agents [17].
Nrf2 drives expression of a battery of Phase II detoxiﬁcation and
antioxidant enzymes via its interaction with the antioxidant response
element (ARE) [24,25]. When activated, this “programmed cell life”
response is neuroprotective and conversely, attenuation of this path-
way can enhance neuronal sensitivity to a range of neurotoxic
challenges [15,26]. Dysregulation has been observed in ALS cellular
models and conﬁrmed in human tissue. We have previously demon-
strated that both Nrf2 and multiple Nrf2 target genes showed
decreased expression in a motor neuronal cell line expressing mutant
(G93A) human SOD1 [27] and that the Nrf2 target, peroxiredoxin
3 (PRDX3), a mitochondrial antioxidant enzyme, is down-regulated in
this cellular model and in human tissue from familial and sporadic ALS
[28]. A reduction of Nrf2 transcripts and protein in spinal motor
neurons and motor cortex from cases of sporadic ALS has also been
described [29]. Astrocyte-speciﬁc expression of Nrf2 delayed the onset
and extended survival in two mouse models of ALS [30]. This pathway
thus represents an attractive therapeutic target due to its disease-
speciﬁc dysregulation in ALS and the compelling evidence for a role of
oxidative stress in disease progression. In addition, it is a well-deﬁned
target, amenable to activation by small molecules and activation of
intrinsic cellular defence mechanisms may confer a more effective and
enduring protection against oxidative stress than, for example, direct
free radical scavenging.
A number of molecules have been described that activate the Nrf2-
ARE pathway. These molecules tend to be natural products such as
dietary ﬂavanoids and cyclic sulfur-containing compounds [14]. These
are not ideal therapeutic candidates, often with limited capacity to
cross the blood brain barrier. The primary aim of the present program
was to screen a commercial small molecule library containing both
marketed drugs and natural products, with a view to identifying Nrf2-
ARE activators which have the capacity to penetrate the CNS and be
rapidly translated to clinical testing. We designed a comprehensive
in vitro screening cascade culminating in assays of motor neuron
survival in primary motor neuron/astrocyte cocultures. Of the 44
compounds initially identiﬁed, S[+]-apomorphine was selected forrigorous in vivo testing, including full pharmacokinetic analysis and
its ability to activate the Nrf2-ARE pathway in the mammalian CNS.
It was subsequently evaluated for neuroprotective potential in
SOD1G93A transgenic mice using objective and quantitative mea-
sures of disease progression. Finally, S[+]-apomorphine was eval-
uated in both sporadic and mutant SOD1-related ALS patient
ﬁbroblasts, which represent a peripherally accessible cellular model
of human ALS. This is the ﬁrst assessment of a CNS penetrating, Nrf2
activating small molecule which has followed the recommenda-
tions on preclinical studies in ALS mouse models [31] and which
has evaluated the therapeutic potential in an in vitro model of
human ALS.Results
Reporter assay validation and library screening
In order to screen the 2000 compound Spectrum collection of
known drugs and natural products, Nrf2-ARE reporter cell lines were
generated in Chinese hamster ovary (CHO) cells and validated using
known Nrf2 inducers tert-butyl hydroquinone (tBHQ) and the ﬂavo-
noid epigallocatechin-3-gallate (EGCG, Supplementary Fig. 1a). The
Spectrum library was screened twice, with compounds at 10 μM and
simultaneous measurement of toxicity in both the reporter and the
control cell lines. Example screening results for one 384-well plate are
shown in Fig. 1A. A total of 44 compounds were identiﬁed as hits
(positive response in both independent screens, no false positive
response in the control cell line, and no evidence of toxicity) and
assessed in full concentration response curves in the same assay
(Fig. 1B). Most compounds showed toxicity at higher concentrations
and a narrow window of Nrf2-ARE pathway activation, typical of
molecules which activate this pathway.
Summary data for the hit ARE-inducing compounds emerging
from this assay are shown in Supplementary Table 1 with a brief
description of the known bioactivity of these compounds. The most
potent ARE inducer was the natural product andrographolide, the only
compound with a submicromolar EC50 (740 nM). This compound
comes from the herb Andrographis paniculata, and is used widely in
Chinese and Indian herbal medicine. There were 24 other natural
products, and 19 synthetic small molecules or natural product
derivatives and of these a total of 6 molecules were approved drugs,
including R[–]-apomorphine, a dopamine agonist approved for the
treatment of Parkinson’s disease.
Pharmacophore for hit molecules
To rationalize the biological results, we attempted to identify a
general pharmacophore for the hit compounds reported in
Supplementary Table 2 using the Pharmacophore Elucidator imple-
mented in MOE [Molecular Operating Environment (MOE 2007.09),
Chemical Computing Group, Inc. Montreal, Quebec, Canada. http://
www.chemcomp.com]. The pharmacophore that emerges is consistent
with known Nrf2 activators which act by electrophilic attack of
sulfhydryl groups on Keap1, the cytoplasmic Nrf2 regulator (Fig. 1C
and D), although further experiments would be required to deﬁnitively
prove this mode of action for the compounds identiﬁed in our assay.
Effects of Nrf2-ARE-inducing hit compounds on oxidative stress
induced by serum withdrawal in motor neuronal and astrocytic cells
To select the best candidates for further assessment we determined
the potential of the 44 hit compounds to limit oxidative stress in CNS
relevant cell types—a motor neuronal cell line (NSC34 cells) and rat
(C6) and human (1321N1) astrocyte cell lines. The cell lines were
pretreated with each of the hit compounds, at a range of
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Fig. 1. Compound library screening results. (A) Example Spectrum library screening data for one 384-well plate. GFP ﬂuorescence versus well number. Wells 1–24 and
360–384 contain alternate positive (10 mM ebselen) and negative (vehicle) controls. Dotted line represents the average +3 SD of the negative controls and all compounds above
this line are counted as “hits.” (B) Overlaid concentration response curves for all 44 hit compounds. Note that the proﬁles for many of the hit compounds follow a bell-shaped
dose response curve, and have a narrow window of ARE induction. (C) Pharmacophore showing alignment of the 24 molecules with an EC50 of less than 10 mM in the primary
screen (Supplementary Table 2) presented two common features: an aromatic/hydrophobic moiety and a hydrogen bond acceptor moiety. (D) When the 1321N1 astrocyte
oxidative stress assay results (Supplementary Table 3) were used for constructing the pharmacophore with a 3 mM activity threshold, one additional common aromatic/
hydrophobic feature was identiﬁed. Aromatic/hydrophobic feature in green, hydrogen bond acceptor feature in blue. This basic pharmacophore is consistent with known Nrf2
activators which may act by electrophilic attack of sulfhydryl groups on Keap1, the cytoplasmic Nrf2 regulator. The most potent compound from the primary screen,
andrographolide (E), had an EC50 in this assay of 0.74 mM. One of the most potent and least toxic compounds in the secondary screens, S[+]-apomorphine is shown in (F).
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compound was then removed and the cells subjected to a 6-h serum
withdrawal to induce oxidative stress. Oxidative stress was measured
using dichloroﬂuorescein (DCF) ﬂuorescence and the degree of
protection is shown as percentage reduction in DCF ﬂuorescence for
each of the three cell lines in Supplementary Table 2, with the IC50,
where available. Hit compounds were much less likely to show
protective effects and more likely to increase oxidative stress in the
motor neuronal cell line compared to the astrocyte cell line. Only 9/44
compounds reduced the oxidative stress DCF signal induced by serum
withdrawal in NSC34 cells, whereas 17/44 increased the DCF signal
(prooxidant). This compares to 29/44 and 32/44 protective compounds
and 1/44 and 0/44 prooxidant compounds in the 1321N1 and C6
astrocytic cell lines, respectively. Since we were interested in identify-
ing neuroprotective compounds, those compounds with a prooxidant
effect in the NSC34 oxidative stress assay and known cytotoxic
molecules were excluded, leaving 22 compounds
Selection of likely CNS penetrant compounds
We next calculated the chemical/physical properties of the com-
pounds, summarised in Supplementary Table 2. ALogP (log10 of thepartition coefﬁcient in octanol/water) andmolecular polar surface area
(mPSA) allow crude prediction of likely CNS penetrance. The Lipinski
ﬁlter excludes compounds which are non-“drug-like.” Selection of
compounds was reﬁned based on the following criteria: AlogP>1, o4,
mPSAo100. Applying these criteria to the remaining 22 molecules
left 17 molecules for further investigation. These molecules are shown
in Table 1 and are designated the “best hit” molecules.
Nrf2-ARE-inducing activity of the best hit compounds in neuronal
and astrocytic cell lines
In order to determine whether the difference in protection in
astrocytic and motor neuronal cell lines was due to differences in the
degree of activation of the Nrf2-ARE pathway in these cell types, the
Nrf2-ARE reporter construct was expressed in astrocytic (C6) and
motor neuronal (NSC34) cell lines. The 17 best hit molecules were
then screened in each cell line (Fig. 2A). We also screened the S[+]
enantiomer of apomorphine. The R[–] enantiomer has dopamine
agonist activity and is used in man, whereas the S[+] enantiomer
lacks this dopaminergic activity [32]. In general, activation of the Nrf2-
ARE pathway in the C6 cells was similar to that seen in the CHO cell
line. The NSC34 reporter cell line showed minimal, if any, activation
Table 1
Proﬁle of 17 best hit compounds with antioxidant or neutral effects in NSC34 cells following serum withdrawal.
Name NSC34 oxidative stress assay 1321N1 oxidative stress assay C6 oxidative stress assay Calculated
properties
IC50
(μM)
Max reduction
(%)
Toxic dose
(μM)
IC50
(μM)
Max reduction
(%)
Toxic dose
(μM)
IC50
(μM)
Max reduction
(%)
Toxic dose
(μM)
ALogP mPSA
2,6-Dihydroxy-4-methoxytoluene 3.26 28 None NA 40 None 5.29 16 10 1.815 49.68
Apomorphine hydrochloride 0.174 25 10 1.7 79 None 1.69 62 None 3.498 43.7
4-Methoxychalcone NA 24 None 3.6 30 None 3.55 82 None 3.685 26.3
Securinine NA 20 None 18.3 55 None 0.645 67 None 1.448 29.53
Levulinic acid NA 15 None 3.31 58 None 7.69 62 None 1.652 54.37
3-α-Hydroxygedinin NA 14 10 NA 25 None 3.22 42 None 3.83 85.97
Hydroquinone NA 0 None 3.38 80 None 7.07 67 None 1.346 40.46
Andrographolide NA 0 10 0.501 35 10 0.192 69 10 2.056 86.99
Deacetylgedunin NA 0 None 2.37 28 10 5.36 70 None 2.97 89.26
3β Hydroxydeoxydesacetoxy-7-
oxogedunin
NA 0 3 3.96 62 None 3.07 67 None 2.683 89.26
Isogedunin NA 0 1 NA 10 None NA 3.349 95.34
Deoxyandirobin lactone NA 0 None 1.64 65 None 2.87 38 None 3.399 85.97
Parthenolide NA 0 1 28.4 47 None 3.11 81 None 2.923 38.82
Epoxy(4,5α)-4,5-dihydrosantonin NA 0 3 0.662 63 None 2.13 62 None 1.598 55.89
3 Acetoxypregn-16-en-12,20-
dione
NA 0 None 12.4? 75 None 5.34 50 None 3.213 60.44
Thymoquinone NA 0 None 11 25 None 0.014 32 None 2.288 34.14
Dalbergione NA 0 None 64 38 None 46 40 None 2.94 34.14
The 44 hits from the library screen were assayed in a motor neuronal cell line (NSC34) for ability to protect the cells from a 6-h oxidative stress insult (serum withdrawal)
after a 24-h preconditioning with compound at various concentrations. Similar assays were utilised in two distinct astrocyte cell lines (1321N1 and C6). In addition,
calculated physical/chemical properties (molecular polar surface area and ALogP) were determined using Pipeline Pilot. Maximum % inhibition of oxidative stress measured
by DCF ﬂuorescence and IC50 for the inhibition are shown. In addition the minimum dose at which toxicity was observed is shown. NA, not applicable (insufﬁcient data, no
concentration response or no inhibition). Compounds are sorted by protective capacity in the NSC34 cell line. ARE inducers were far more effective at protecting the astrocyte
cell lines (1321N1 and C6) from oxidative stress compared to NSC34 cells. In order to select compounds for further assessment the following criteria were applied: protective
or neutral effect in the NSC34 cell line, AlogP>1, o4, mPSAo100, lack of known toxicity in vivo.
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[+]-apomorphine which showed activation at 1 μM and above. This
suggests that the underlying cause for greater protection against
oxidative stress in astrocytic cell lines versus motor neuronal
(NSC34) cells was due to a much more robust activation of the Nrf2-
ARE pathway in astrocyte cell lines for most of the compounds. The S
[+] enantiomer of apomorphine was equally potent in terms of Nrf2-
ARE activation compared with the R[–] enantiomer in C6 cells,
indicating that this activity is unrelated to dopamine receptor
activation.
The key objective of this program of work was to identify
molecules that could be fast-tracked for clinical testing in ALS,
having been used previously in man. Of the 17 best hit molecules,
two had a history of use in man as natural products (securinine,
andrographolide) and one was a currently approved drug used for
treatment of motor ﬂuctuations in Parkinson’s disease (R[–]-apo-
morphine hydrochloride). Andrographolide and the S[+] enantio-
mer of apomorphine were selected for further assessment as the
clinical experience for securinine is restricted to the former USSR and
this compound is known to have convulsant properties [33]. The S[+]
enantiomer of apomorphine was considered an attractive candidate
for therapeutic assessment because it lacks the unwanted effects of the
parent molecule (i.e., dopamine agonism, induction of emesis)
Induction of ARE target gene expression and function in C6 cells and
primary mouse astrocytes by andrographolide and S[+]-apomorphine
To conﬁrm that these “lead inducers” were able to activate the
Nrf2-ARE pathway, quantitative RT-PCR (Q-RTPCR) for Nrf2 target
genes NADPH quinone oxidoreductase 1 (NQO1) and heme
oxygenase-1 (HO-1) was performed in C6 cells (Fig. 2B and C) and
primary mouse astrocytes (Fig. 2D and E) following treatment with
andrographolide and S(+)-apomorphine at EC50 and EC90 concentra-
tions (as determined in the Nrf2-ARE reporter assay in C6 cells) and
gene induction was observed in most conditions. Further experimentswere conducted in Nrf2 −/− mouse embryonic ﬁbroblasts (MEFs) to
conﬁrm that Nrf2 was essential to the response (Fig. 3A and B). In
wild-type MEFs, both S[+]-apomorphine and andrographolide
enhanced NQO1 protein expression by 3.1-fold and 3.6-fold, respec-
tively, when dosed at EC90 concentrations. This compared to a similar
level of expression in Nrf2−/− MEFs for andrographolide at EC90
concentrations (0.92-fold change versus vehicle) as opposed to a
reduction in expression for S[+]-apomorphine at EC90 concentrations
(0.36-fold change versus vehicle). Induction of HO-1 at the RNA level
was associated with a dose-dependent enhancement of protein
expression as demonstrated by immunoﬂuorescence staining
(Fig. 3C and D).
An important functional effect of this enhanced antioxidant
capacity was demonstrated by measuring total glutathione levels
under the same conditions in both primary astrocytes and in the
media collected from treated astrocytes (Fig. 4A and B). Glutathione
levels were elevated within both the astrocytes and the media—
highlighting onemechanism bywhich Nrf2-responsive astrocytes may
protect neighbouring, less ARE responsive, MNs from oxidative
challenge.
Nrf2 Inducers protect motor neurons from oxidative stress in primary
mouse astrocyte/motor neuron cocultures
Cocultures consisting of primary mouse motor neurons (MNs)
on an astrocyte feeder layer were exposed to an oxidative insult
following pretreatment with either andrographolide or [S+]-apo-
morphine (Fig. 4C). The cocultures were then challenged for 6 h
with 10 mMmenadione to induce oxidative stress and MNs stained
and counted. In DMSO control cultures an approximately 25%
reduction in MN number was observed. In cocultures treated with
either andrographolide or [S+]-apomorphine, signiﬁcant neuro-
protective effects were observed, expressed as a preservation of
MN numbers in the presence of menadione induced oxidative
stress (Fig. 4C).
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Fig. 2. Hit compounds activate Nrf2-ARE directed transcription in C6 and primary mouse astrocytes. ARE reporter assay in C6 astrocyte cell line (C6-ARE) and NSC34 cell line (NSC34-
ARE) for 17 best hit compounds and S[+]-apomorphine (A). Overall the response in C6-ARE is similar to that seen in the CHO-ARE cell line and both R[–] and
S[+]-apomorphine induce the Nrf2-ARE pathway to a similar degree, although the R enantiomer shows toxicity at the highest dose (30 mM), suggesting that Nrf2 activation is
unrelated to the dopamine agonist activity of R[–]-apomorphine. The response in the NSC34 cell line was substantially reduced or nonexistent for the majority of compounds, although
S[+]-apomorphine shows some activation. Quantitative RT-PCR analysis for Nrf2-regulated genes in the rat C6 astrocyte cell line (B and C) and primary mouse astrocytes (D and E)
following 24-h treatment with andrographolide (andro) and S[+]-apomorphine (S[+] apo) at EC50 and EC90 concentrations, as determined in
C6–4xARE-TK reporter cells. Two key ARE genes, heme oxygenase 1 (HO-1, B and D) and NADPH quinone oxidoreductase-1 (NQO1, C and E), showed statistically signiﬁcant changes
in gene expression in both the rat C6 astrocytic cell line and the primary mouse astrocytes. Asterisks indicate signiﬁcant difference from DMSO control by one-way ANOVA, *Po0.05,
**Po0.01, ***Po0.001.
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Fig. 3. Andrographolide and S[+]-apomorphine increase antioxidant protein expression via activation of Nrf2 following treatment at EC50 and EC90 concentrations (as determined in
C6–4xARE-TK reporter assay) for 24 h. (A) Western blotting for NQO-1 protein induction by S[+]-apomorphine and andrographolide in Nrf2 gene deleted mouse embryonic ﬁbroblasts
(Nrf2 −/−MEFs) andwild type (Nrf2 +/+MEFs) controls. NQO-1 was probed in RIPA lysates of MEFs using a polyclonal antibody; α-tubulinwas probed as a loading control. NQO-1 gave
a calculated molecular weight of 27 kDa and alpha-tubulin 54 kDa. The overall level of NQO-1 expression was lower generally in Nrf2 −/− MEFs, necessitating longer exposures for
detection. (B) Densitometry analyses from two independent Western blotting experiments showing fold induction of NQO-1 over vehicle control, both S[+]-apomorphine and
andrographolide show a>3-fold induction of NQO-1 at EC90 concentrations in wild-type MEFs, whereas there is no induction in Nrf2−/− MEFs. (C) Immunoﬂuorescence staining for
heme oxygenase 1 (HO-1) in primary mouse astrocytes. (D) Area and staining intensity were quantiﬁed using Image J and used to calculate a staining index. A signiﬁcant increase in
HO-1 staining was observed following treatment with EC90 concentrations of S[+]-apomorphine and andrographolide compared to DMSO control (one-way ANOVA with Bonferroni
post tests, **Po0.01, *Po0.001).
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G93A SOD1 expressing astrocytes
Previous work had demonstrated an attenuated Nrf2 response in
motor neuronal cell lines expressing mutant SOD1, and in postmortem
tissue from human cases of SOD1-related ALS [27,29]. It was therefore
important to determine whether our lead inducers could still activate
the Nrf2 pathway in astrocytes expressing G93A mutant SOD1. Q-
RTPCR was performed and demonstrated a signiﬁcant increase in
transcripts for NQO1 and HO1 following a 24-h pretreatment withandrographolide and S[+]-apomorphine at their EC90 concentrations
and for andrographolide at its EC50 concentration (Fig. 4D and E).
Preclinical efﬁcacy of S[+]-apomorphine in the SOD1G93A mouse
model of ALS
CNS bioavailability of both R[–] and S[+]-apomorphine has
been previously described [34]. For this reason we selected
S[+]-apomorphine for proof of concept studies in vivo in the
SOD1G93A mouse model of ALS. A rational approach, mirroring
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and aggressive preclinical model. First, pharmacokinetic (PK)
analysis was conducted (Fig. 5A) in normal C57Bl/6 mice following
intravenous dosing at 1 mg/kg with assessment of drug levels in
plasma, brain, and cerebrospinal ﬂuid (CSF) by LC/MS-MS. To
assess oral bioavailability, S[+]-apomorphine was also dosed
orally at 10 mg/kg and the plasma time curve established (seeSupplementary Table 3 for calculated pharmacokinetic para-
meters). Plasma half-life was short (∼11 min), although similar to
that described previously for R[+]-apomorphine. Brain uptake was
calculated as the area under the curve to inﬁnity (AUCinﬁnity) in
brain tissue divided by the AUCinﬁnity in plasma. A value of 228%
was calculated, indicating CNS penetration of the parent com-
pound. Since subcutaneous (sc) bioavailability is almost 100% [35],
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Fig. 5. In vivo proﬁling of S[+]-apomorphine. (A) Pharmacokinetic (PK) analysis was conducted in normal C57Bl/6 mice following both intravenous (iv, 1 mg/kg) and oral
(po, 10 mg/kg, n¼3 per time point po and 4 per time point iv). For calculated PK parameters see Supplementary Table 4. (B) Measurement of HO-1 and NQO1 gene expression
in whole spinal cord at 6, 24, 48, and 84 h postdosing with 5 mg/kg S[+]-apomorphine via the sc route. (C–H) Female SOD1G93A transgenic mice were dosed from Day 21
until end-stage (n¼13–15 per group), daily with 5 mg/kg S[+]-apomorphine sc. A pronounced decline in rotarod performance is observed in our model from p40 in
SOD1G93Acontrol mice (C); this initial decline was signiﬁcantly delayed by treatment with S[+]-apomorphine as assessed by the time taken to reach a 20% decline in rotarod
performance (D, median 6 weeks for vehicle-dosed mice, 8 weeks for S[+]-apomorphine-dosed mice, P¼0.0033 Mann-Whitney U test). At later stages of disease, gait
analysis showed a signiﬁcant delay in decline of both fore-limb (E) and hind-limb (F) stride length for S[+]-apomorphine-treated mice (two-way ANOVA with Bonferroni
post test). (G) Immunoﬂuorescence staining for motor end plates (alpha-Bungartoxin, red) and presynaptic processes (combined synaptophysin and neuroﬁlament, green) in
gastrocnemius muscle of vehicle and S[+]-apomorphine-treated mice at 60 days of age showed a signiﬁcant protection against loss of innervation (H, Student's t test, n¼3
per group). (I) Measurement of oxidised and (R) reduced glutathione levels in spinal cord at 60 days showed a signiﬁcant reduction in oxidised glutathione levels and a
higher GSH/GSSG ratio (K) in S[+]-apomorphine-treated mice (n¼7 per group). *Po0.05, **Po0.01, ***Po0.001.
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R.J. Mead et al. / Free Radical Biology and Medicine 61 (2013) 438–452446the sc route was selected and dose levels of 2.5 and 5 mg/kg were
tested for ability to induce Nrf2-regulated gene expression in the
spinal cord (Fig. 5B). Gene expression of both HO-1 and NQO1 was
assessed by Q-RTPCR in whole spinal cord at 6, 24, and 48 h
postdosing and 5 mg/kg gave a 3.5-fold HO-1 gene induction at
48 h. Physiologically based pharmacokinetic (PBPK) modeling was
also used to determine the likely CNS concentrations following
these subcutaneous doses of 2.5 and 5 mg/kg (Supplementary
Fig. 2). The PBPK model was able to describe the observed plasma
concentrations after intravenous (iv) and oral dosing and the total
brain concentrations observed after iv dosing (Supplementary
Figs. 2a–c). Simulations of the exposure following sc administra-
tion at 2.5 and 5 mg/kg predict that maximal plasma concentra-
tions at the lower dose were in the range of 1.2–1.9 μM (Supple-
mentary Fig. 2d) and at the higher dose were in the range of 2.4–
3.8 μM (Supplementary Fig. 2e). Concentrations in brain were in
the range of 2.7–4.3 and 5.4–8.5 μM at doses of 2.5 and 5 mg/kg,
respectively (Supplementary Figs. 2f and g), possibly explaining
the differences in gene induction seen with these two doses.
As the drug was able to access the CNS and induce gene
expression, a full pharmacology study in SOD1G93A transgenic
mice was initiated (n¼15/group) dosed from Day 21 until end-
stage, daily with 5 mg/kg S[+]-apomorphine sc. The rotarod test
(Fig. 5C and D) was performed weekly and semiautomated gait
analysis using the Catwalk system (Fig. 5E and F) was performed
every 2 weeks from Postnatal Day 42 (p42) to p112. A pronounced
decline in rotarod performance is always observed in our model
from p40 in mSOD1G93A mice [36]. This initial decline of motor
function was signiﬁcantly delayed by treatment with S[+]-apo-
morphine (Fig. 5C) as assessed by the time taken to reach a 20%
decline in rotarod performance (Fig. 5D, median 6 weeks for
vehicle-dosed mice, 8 weeks for S[+]-apomorphine-dosed mice,
P¼0.0033, Mann-Whitney U test). At later stages of disease, gait
analysis showed a signiﬁcant delay in decline of both fore-limb
(Fig. 5E) and hind-limb (Fig. 5F) stride length for S[+]-apomor-
phine-treated mice (two-way ANOVA with Bonferroni post test).
A separate group of mice was assessed for the degree of gastro-
cnemius muscle innervation (Fig. 5G and H) and reduced and
oxidised glutathione levels at 60 days of age (Fig. 5I, J, and K).
A signiﬁcant increase in muscle innervation was observed with
S[+]-apomorphine treatment (Figs. 5H, 39.5% versus 28.1%,
P¼0.0340, Student’s t test) and a signiﬁcant reduction in oxidised
glutathione levels in spinal cord (Figs. 5J, 4.2 μM71.0 versus
7.1 μM70.67, P¼0.038, Student’s t test). Despite signiﬁcant slow-
ing of disease progression, we did not observe a signiﬁcant
improvement in survival (measured by failure of the righting
response within 10 s) or motor neuron numbers at end-stage in
the S[+]-apomorphine-treated group.Fibroblasts from ALS patients display elevated levels of oxidative
stress which can be attenuated with S[+]-apomorphine
In order to establish the relevance of S[+]-apomorphine as a
potential therapy in human ALS, we isolated primary ﬁbroblasts
from both sporadic and I113T mutant SOD1-related ALS patients.
These ﬁbroblasts showed an elevated level of oxidative stress
compared to control ﬁbroblasts (Fig. 6A and B) and represent a
useful model for screening candidate antioxidants. When
S[+]-apomorphine was tested at 0.4 and 4 mM, a signiﬁcant
reduction in basal oxidative stress was observed in both sets of
the patient ﬁbroblasts but not in the control ﬁbroblasts at 4 mM
(approximate EC50 concentration, Fig. 6C). S[+]-Apomorphine was
also able to protect against menadione-induced cell death in ALS
patient ﬁbroblasts (Fig. 6D and E).Discussion
The objective of this program of work was to identify potent
Nrf2-inducing molecules with the potential to penetrate the CNS
and a previous history of safe use in man, enhancing the potential
for rapid clinical development. Screening a library of 2000 drugs and
natural products led to the identiﬁcation of 44 molecules, which had
the capacity to activate the Nrf2 pathway in a reporter cell line.
The approach used was particularly suited to the Nrf2 pathway
because many small molecule compounds (natural and synthetic)
are known to activate this pathway, although such activation is
often linked with toxicity. Of the compounds identiﬁed, one
natural product (andrographolide) and the receptor inactive
enantiomer of a clinically approved dopamine agonist (S[+]-apo-
morphine) were selected for further investigation.
Andrographolide is the principal active component in extracts
of the herb Andrographis paniculata [37] which is widely used in
Indian herbal medicine as an anti-infective, anti-inﬂammatory and
hepatoprotective agent. Andrographolide, a diterpene lactone, has
not previously been shown to directly activate the Nrf2-ARE
pathway, although its antioxidant capability has been recognised
[38,39]. Clearly, the activation of the Nrf2-ARE pathway that we
have identiﬁed provides a deﬁned mechanism by which andro-
grapholide can mediate these antioxidant effects. However, there
are no data on the distribution of andrographolide in the CNS as
far as we are aware and andrographolide appears to be a substrate
for P-glycoprotein [40], one of the major efﬂux transporters in
brain endothelium [41] which is predicted to inhibit efﬁcient
delivery of andrographolide to the CNS.
In contrast, apomorphine has established CNS activity and is
known to partition to the CNS. R[-]-Apomorphine is a nonselective
dopamine D1/D2 agonist. It shows more potent D2-like (D2, D3,
and D4) activity, reﬂected in high binding afﬁnity for D4 receptors
(Ki¼4.4 nM), and more limited D1-like (D1 and D5) activity, with
low binding afﬁnity for D1 receptors (Ki 370 nM) [42]. Originally
used as an emetic, it is administered parenterally for the rescue of
“off” episodes in Parkinson’s disease (PD) [43]. Apomorphine has a
well-described pharmacokinetic proﬁle in man [35,44,45] and in
rats, demonstrating signiﬁcant accumulation in the CNS [46].
Although R[–]-apomorphine is a potent dopamine agonist, the
S[+] enantiomer is not [47] and evaluation in in vivo models of
dopamine receptor activation failed to evoke a response at doses
up to 25 times those required with R[–]-apomorphine [32]. In
addition, S[+]-apomorphine failed to induce emesis in dogs at
doses 10-fold greater than those required with R[–]-apomorphine
[32]. S[+]-Apomorphine can antagonise the effects of R[–]-apo-
morphine and although it has some D1/2 antagonist activity [47]
this is very unlikely to explain the improvement in parameters of
motor function seen in our mouse model since it is rapidly cleared
(T1/2 11 min, Supplementary Table 4) and D1 and D2 dopamine
antagonists are known to inhibit rather than enhance locomotor
activity [48,49].
Apomorphine has recognised antioxidant activities. It was able
to inhibit Fenton reaction-mediated lipid peroxidation in rat brain
mitochondrial fractions—attributed to an ability to directly
scavenge ROS [50]; protected rat PC12 cells from oxidative damage
at low micromolar concentrations [51] and reduced MPTP-induced
dopaminergic toxicity in mice [52]. R[–]-Apomorphine was shown
to protect SH-SY5Y cells from 6-hydroxydopamine-induced cell
death via activation of the Nrf2-ARE pathway [53].
We have now demonstrated that both the S[+] and the R[–]
enantiomers of apomorphine are able to activate the Nrf2-ARE
pathway with similar potency and this opens up the interesting
possibility of using the S[+] form as a tool to activate the Nrf2-ARE
pathway in vivo. The advantages of this approach are obvious; the
lack of dopamine agonism and emesis with the S[+] form will
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Fig. 6. Oxidative stress and cell death assays in ﬁbroblasts from ALS and control patients. Fibroblasts from SOD-1-related and sporadic ALS patients display an elevated level
of oxidative stress which is signiﬁcantly attenuated by treatment with S[+]-apomorphine. (A) Effect of the I113T SOD1 (n¼3 cases) mutation on oxidative stress, measured
using dichloroﬂuorescein (DCF) ﬂuorescence in human ﬁbroblasts from three patients under basal conditions in media with (+/+) and without (+/–) glutamine compared to
control patients (n¼3 cases) under the same conditions. (B) Oxidative stress in ﬁbroblasts of sporadic ALS patients (n¼2 cases) under the same conditions compared to
control patients (n¼3 cases). (C) S[+]-Apomorphine at a concentration of 4 mM signiﬁcantly reduces oxidative stress, measured as DCF ﬂuorescence, in sporadic and
SOD1-related ALS patient ﬁbroblasts and to a greater extent than the reduction seen in control ﬁbroblasts which is nonsigniﬁcant. Fibroblasts from a control (D), an I113T
SOD1 patient (E), and a sporadic ALS patient (F) were treated with 4 mM S[+]-apomorphine (S[+] Apo) with and without exposure to menadione (Men) to induce cell death
measured by MTT assay (see methods). S[+]-Apomorphine signiﬁcantly attenuated cell death in both sporadic and I113T SOD1 ALS cases but not in the control case. Data
analysed by two-way ANOVA with Bonferonni post tests, *Po0.05, **Po0.01.
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clinical studies, yet the desirable properties of CNS partitioning
and Nrf2-ARE activation are maintained.
The protective effects of Nrf2 on motor neurons could be via both
indirect and direct mechanisms. We have shown that induction of
Nrf2 in astrocytes by S[+]-apomorphine promotes antioxidant
defence via enzyme induction and upregulation of intracellular and
extracellular secreted glutathione levels. This enhanced glutathioneproduction could in turn protect neighbouring motor neurons from
oxidative insults in an indirect manner. S[+]-Apomorphine was the
only compound tested which was able to activate the Nrf2 pathway
in a motor neuronal cell line raising the possibility that direct
activation of Nrf2 signaling in motor neurons could also enhance
antioxidant defences.
The pharmacokinetic and pharmacodynamic proﬁle of S[+]-apo-
morphine demonstrates long-term induction of the Nrf2-mediated
R.J. Mead et al. / Free Radical Biology and Medicine 61 (2013) 438–452448response following a relatively short exposure, which translates to a
signiﬁcant beneﬁcial effect on motor function measured using
quantitative and objective measures of disease progression in a
commonly used mouse model of ALS. However we cannot exclude
the possibility that the mechanism of action in vivo may involve
other pathways than enhancement of antioxidant defences. Nrf2
can activate transcription of a wide variety of genes and gene
families including those associated with xenobiotic metabolism,
protein stress response, and inﬂammation [54,55], all of which are
implicated in mutant SOD1-mediated neurotoxicity [1]. In addition
the precise set of genes activated varies with different activators
[55]. The transcriptional response following S[+]-apomorphine
treatment is currently under investigation in our laboratory.
Although no improvement in mouse survival was observed in
our model, improvements in measures of disease progression are
given equal weight to measures of improved survival in the recent
guidelines [31] and this is now becoming more accepted in the
ﬁeld [56]. These parameters also relate to well-deﬁned, early
disease processes [36] shown to be active in human ALS [57]
and therefore have the potential to translate into signiﬁcant
outcome beneﬁts in the more gradually progressive human dis-
ease. Furthermore, the use of survival as an endpoint in the
SOD1G93A mouse model has so far failed to deliver clinically
translatable effects [9] and few of the positive effects on survival
described in this aggressive model have been well replicated [58],
likely due to poor study design in the mixed genetic background
mice (SJLBL6) used in the majority of studies [59]. Indeed there
have been two previous studies using Nrf2-activating molecules in
the SOD1G93A mouse model [60,61], but neither of these studies
has followed the recommended study design [59] for the mixed
SJLBL6 background and the effects reported could well be due to
confounding factors (effect of litter, changes in transgene copy
number).
As proof of concept that activation of Nrf2 might have a
beneﬁcial effect in human ALS, we were able to demonstrate that
S[+]-apomorphine reduced pathologically elevated levels of
oxidative stress in ﬁbroblasts from patients with both mutant
SOD1-related and sporadic ALS, and could reduce oxidative stress-
induced cell death in this human cell model. The combination of
efﬁcacy in a clinically translatable readout (motor function in
SOD1G93A mice) and reduction in oxidative stress observed in
ﬁbroblasts from ALS patients gives conﬁdence in progressing
S[+]-apomorphine toward the clinic. This is the ﬁrst time that a
clinically acceptable, CNS penetrant molecule has been shown to
activate the Nrf2-ARE pathway in vivo and ameliorate disease
measures in both mouse and patient ﬁbroblast models of ALS.
The next stages in this program entail development of biomar-
kers of drug action to enable proof of mechanism studies in man,
an approach already taken in oncology in so-called “Phase 0”
clinical studies [62]. We believe this represents a rational and
expeditious approach to bring to the clinic new therapeutic
approaches for ALS and potentially for other CNS disorders
associated with oxidative stress.Materials and methods
Cell culture
Chinese hamster ovary (CHO), NSC34 mouse motor neuronal cells
[63] C6 (rat), and 1321N1 (human) astrocytic lines were routinely
maintained in DMEM supplemented with 10% FBS and penicillin/
streptomycin. The ARE-TK-GFP and TK-GFP reporter constructs were
a kind gift from William E. Fahl McArdle Laboratory for Cancer
Research, University of Wisconsin. The TK-EGFP reporter construct
consists of a 123-bp thymidine kinase promoter inserted in themultiple cloning site of pEGFP (Clontech) and the ARE-TK-EGFP also
contains four repeats of a 41-bp GST ARE motif (TAGCTTGGAAATGA-
CATTGCTAATCGTGACAAAGCAACTTT) 3′ to the TK promoter [64].
These plasmids were transfected into CHO, C6, and NSC34 cell lines
using Lipofectamine 2000 (Invitrogen) and following 10–14 days of
selection in 0.5 mg/ml G418 they were expanded and selected for
basal eGFP expression using ﬂuorescence-activated cell sorting (BD,
FACSAria) with two sequential cell sorts for each cell line. These
mixed populations of stable transfectants with basal eGFP expression
were used in subsequent assays and designated 4xARE-TK-GFP for
the ARE-containing line and TK-GFP for the control cell line. The
NSC34 cell lines stably expressing G93A mutant hSOD1 have been
described previously [65]. In brief, NSC34 cells were transfected with
G93A mutant SOD1 and stably transfected single cell clones were
isolated by selection in 250 μg/ml G418 and cloning by limiting
dilution. Mouse embryonic ﬁbroblasts were generated and main-
tained as described previously [66].
ARE reporter assay—Spectrum library screen validation
In order to screen the Spectrum library of 2000 small molecule
drugs and natural products the TK-GFP CHO ARE reporter cell line
was subjected to a Z′ score assay [67] in a 384-well plate (Greiner
Bio-one, μClear, black) using a range of plating densities
(5–20104/well plated 24 h prior to assay) and different media.
Alternate wells were incubated with 10 μM Ebselen and vehicle
(0.1% DMSO) for 24 h followed by replacement of media with PBS
containing 0.3 μM ethidium homodimer-1 (EthD1, Molecular
Probes, Paisley, UK). This concentration of Ebselen represents an
approximate EC90 for this drug. GFP ﬂuorescence (ARE induction)
was then measured at Ex485 nm/Em530 nm using a Fusion universal
plate reader (Packard Bioscience). The Z′ score was calculated as
follows
Z′¼ 1−ð3SD
þ þ 3SD−Þ
ðAveþ–Ave−Þ
where SD+ ¼ standard deviation of positive control wells; SD− ¼
standard deviation of negative control wells; Ave+ ¼ average
ﬂuorescence reading of positive control wells; Ave− ¼ average
ﬂuorescence reading of negative control wells.
Signal to noise (S/N¼ Ave+/SD+) and signal to background (S/B
¼ Ave+/Ave−) ratios were also determined for the different assay
conditions. Acceptable Z′ scores were >0.5.
For the library screen, cells were plated at a density of 20104
in normal DMEM media containing 10% FBS on Day –1 and on Day
0, cells were incubated for 24 h with drug in serum-free media.
Media was removed by hand and replaced (1 compound/well)
with the Spectrum library diluted to 10 μM in 0.1% DMSO using a
Q-bot liquid handling system (Genetix, New Milton, UK). The
media were removed after 24 h and replaced with the same
volume of PBS containing 0.3 μM EthD1. GFP ﬂuorescence (ARE
induction, Ex485 nm/Em530 nm) and Eth D1 ﬂuorescence (toxicity
Ex530 nm/Em645 nm) were then measured. The TK-GFP CHO ARE cell
line was screened twice in a single point assay and the control
TK-GFP CHO cell line was screened once to eliminate false
positives.
ARE reporter assay—Determination of EC50
Reporter assays were run as for the library screen with a
concentration curve ranging from 0.01 to 100 μM drug in triplicate
in FCS-free DMEM for 24 h. Nonlinear regression was used to ﬁt a
sigmoidal dose–response curve on a semi-Log plot to calculate the
EC50 using GraphPad Prism (GraphPad Software). The reporter
assay was performed similarly in C6 and 1321N1 astrocyte cell
lines stably transfected with the 4xARE-TK-GFP and TK-GFP
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read prior to washing the cells and reading the GFP signal.
Oxidative stress assay
The NSC34, C6, and 1321N1 cells were plated in 96-well tissue
culture plates to achieve 30% conﬂuency and incubated with drug in
triplicate wells as a 9 point titration (100 mM to 10 nM) for 24 h. Cell
density was observed to ensure that no signiﬁcant toxicity or growth
inhibition occurred. Media were then replaced with serum-free,
phenol-free media for 5 h. Carboxy-H2DCFDA (6-carboxy-2′,7′-
dichlorodihydroﬂuorescein diacetate, di(acetoxymethyl ester), and
EthD1 were added to the cells to ﬁnal concentrations of 5 and
0.3 μM, respectively. Carboxy-H2DCFDA and EthD1 ﬂuorescence was
read at Ex485 nm/Em530 nm and Ex530 nm/Em645 nm, respectively, after
1 h. Cell survival assay was then performed on the cells as protection
is measured as percentage reduction in carboxy-H2DCFDA signal;
therefore data points were excluded where a decrease in cell number
was measured.
Cell viability assay
The method used was essentially as described previously [65].
Brieﬂy methylthiazolyldiphenyl-tetrazolium bromide (MTT) was
added to the cells and a blank well to a ﬁnal concentration 0.5 mg/ml
and incubated at 37 1C for 1–3 h depending on the cell line used.
Cells and reaction product were solubilised in 20% SDS/50% DMF for
1 h with shaking at room temperature before reading the absorbance
at 595 nm.
Pharmacophore development and modeling
All molecular modeling studies were performed on a MacPro
dual 2.66GHz Xeon running Ubuntu 8. Compounds were built with
Molecular Operating Environment (MOE) 2007_09 and minimized
using the MMFF94x force ﬁeld until a RMSD gradient of 0.05
kcal mol−1 Å−1 was reached. The Pharmacophore Elucidator imple-
mented in MOE was used to generate a pharmacophore, perform-
ing a full conformational search on the compounds selected.
Primary mouse motor neuron/astrocyte cocultures
Mouse glial cultures were established based on published
methods [68,69]. Primary spinal cord motor neurons (MNs) were
cultured from E13.5 C57Bl/6 mouse embryos as described pre-
viously [70]. Cocultures were allowed to establish for 2 weeks and
neuroprotection assays performed. Cocultures were exposed to
drug or vehicle for 24 h followed by a 6-h treatment with
menadione (10 μM) to induce oxidative stress or with no stress
to determine the effect of drug alone. Following stress treatment,
coverslips were washed 3 times, ﬁxed, and permeabilised, and
MNs immunostained with SMI32 (Covance, UK). Total MNs were
counted by ﬂuorescence microscopy in a 1.5 cm2 area per cover-
slip. A minimum of three repeats in triplicate were performed per
condition. Both vehicle and drug treatments were counted with
and without stress treatment, and results were analysed by two-
way ANOVA using Bonferroni post tests.
Western blot analysis
Cells were isolated and lysed in a RIPA buffer containing
protease inhibitor cocktail (Roche), quantiﬁed for protein content
by Bradford assay, and loaded 30 μg per sample. Samples were run
on a 12.5% acrylamide gel under reducing conditions with a
prestained marker and transferred to polyvinylidene ﬂuoride
membrane and blocked in 5% milk. Mouse anti-alpha-tubulin,clone DM1A (Sigma), and rabbit anti-NQO1 (kind gift from
Prof. John Hayes, University of Dundee) were used at 1 in 1000
dilution in Tris-buffered saline containing Tween. Polyclonal goat
anti-mouse (Abcam-Ab97040) and polyclonal goat anti-rabbit
(Dako Cat. No. P0448), horseradish peroxidase-conjugated sec-
ondary antibodies were used for detection of relevant primary
antibodies. Bands were visualised by enhanced chemilumines-
cence reagents (Geneﬂow EZ-ECL kit). Relative band intensities
were captured, using subsaturation, and quantiﬁed using a Gbox
iChem XT digital imaging system (Syngene).
Total glutathione assay
Primary astrocytes were grown to conﬂuency in 24-well plates
and then treated with drug (or 0.05% DMSO vehicle) in phenol
red-free DMEM containing 10% FBS and penicillin/streptomycin for
24 h. Conditioned medium was collected and astrocytes were then
washed in ice-cold PBS before addition of 250 μl/well of sulpho-
salicylic acid (SSA, 5% (w/v)). Plates were frozen at −80 1C and
thawed at 37 1C, twice, and then incubated at 4 1C for 15 min. The
supernatant was removed and centrifuged at 13,000 g for 5 min.
Conditioned medium samples were incubated at 80 1C for 15 min
and then centrifuged at 13,000 g for 5 min. Samples were either
used immediately or stored at −80 1C. Reaction mixture (150 μl/well;
100 mM potassium phosphate buffer, pH 7.0, 1 mM EDTA, 6 Units/ml
glutathione reductase, 1.5 mg/ml 5,5′-dithiobis(2-nitrobenzoic acid))
was added to 10 μl of each sample or glutathione standard (0–50 μM
reduced glutathione) in a 96-well plate and incubated at room
temperature for 5 min before addition of 50 μl/well of NADPH
solution (0.16 mg/ml). A412nm was measured every minute for
15 min and the total glutathione concentration (GSH + GSSG) was
calculated from initial rates. Samples were tested in triplicate.
Quantitative RT-PCR
Nrf2 Target gene expression was determined using Q-RTPCR as
described previously [28] using the following primers: Ho-1
forward primer, cac ttc gtc aga ggc ctg cta; Ho-1 reverse primer,
gcg gtg tct ggg atg agc ta; Nqo1 forward primer, cgc ctg agc cca gat
att gt; Nqo1 reverse primer, act gca atg gga act gaa ata tca; GAPDH
forward, gaa acc tgc caa gta tga tga cat; GAPDH reverse, ggt cct cag
tgt agc cca aga t.
In silico analysis
In order to select drug-like molecules for further screening,
Pipeline Pilot (SciTegic, London, UK) was used for in silico analysis.
The molecular polar surface area (mPSA) was calculated for all
2000 molecules from the Spectrum Collection as a crude measure
of likely CNS penetrance [71] and a Lipinski Filter was also applied
to determine which molecules were most drug-like. This ﬁlter
applies the “rule of ﬁve” [72] which selects compounds with a
cLogP o5, molecular mass o500, o5 hydrogen bond donors
(OH+NH count), and o10 hydrogen bond acceptors (O plus N atoms).
Transgenic C57Bl/6 SOD1G93A model of ALS
All mouse experiments were carried out in accord with the
Animals (Scientiﬁc Procedures) Act 1986 under a UK Home Ofﬁce
project license reviewed by the Shefﬁeld University Ethical Review
Committee Project Applications and Amendments Sub-Committee of
the Shefﬁeld University Ethical Review Committee and by the Animal
Procedures Committee (London, UK). Pharmacology experiments in
SOD1G93A transgenic mice were conducted according to the pub-
lished guidelines for studies in this model [31]. Mice were originally
obtained from the Jackson Laboratory, B6SJL-Tg (SOD1-G93A)1Gur/J
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C57Bl/6 background (Harlan UK, C57Bl/6 J OlaHsd) for >20 genera-
tions. Power analysis indicated that 13–15 mice per group would
detect a difference in survival ratio of 10% which is widely accepted
as biologically relevant and could detect a difference in time for
rotarod performance to decline of 1 week. The litters were split to
enable an even distribution of sex and parentage between the two
comparison groups and the groups randomly assigned to treatment
or control. Previous extensive experiments have indicated that this
method of generating control groups provides robust data [36]. Our
model, on a deﬁned inbred genetic background, shows no effect of
sex or litter of origin on survival [36]. Female SOD1G93A C57BL/6J
mice were injected with 10 ml/kg of vehicle (0.1% DMSO in water), or
S[+]-apomorphine at 0.5 mg/ml subcutaneously to give a ﬁnal dose
of 5 mg/kg, daily from 21 days of age through to end-stage (complete
loss of righting reﬂex for more than 10 s). Behavioural assessment
was carried out blinded to treatment group. Rotarod training was
performed over 3 days with 2 trials per day. Subsequently, the
rotarod test was performed once per week in the afternoon. On each
day, mice were tested twice with a rest period in between tests. The
best score was taken for analysis. The rotarod (Ugo Basile 7650) was
set to accelerate from 4 to 40 rpm in 300 s. Latency to fall (s) was
recorded in seconds for each mouse. The test was performed until
mice reached a time of o5 s. The catwalk gait analysis system
(Noldus Instruments, version 7.1) was used to capture gait para-
meters in groups of 5 G93A—transgenic mice and 7 nontransgenic
mice. Mice were tested every 2 weeks from 6 weeks of age to 16
weeks of age. They were placed on the catwalk apparatus in
complete darkness and the recording of gait patterns was performed
in a separate room. Multiple runs were recorded for each mouse and
three selected for analysis. Processing of gait data was performed
using the dedicated software, with the assignment of limbs per-
formed manually and subsequent automated calculation of gait
parameters.
Neuromuscular junction staining
Mice were euthanized by overdose of pentobarbitone and
perfused with PBS; both gastrocnemius muscles were dissected
out and postﬁxed in 4% paraformaldehyde for 20 min, followed by
cryopreservation through 3 successive 5-min incubations in 5, 10,
and 15% sucrose. Specimens were incubated overnight in 20%
sucrose and then embedded in OCT embedding matrix. Thirty ﬁve-
micrometer-thick longitudinal sections were collected. Tissue
sections were dried, permeabilised in blocking solution (0.5%
Triton X-100, 5% BSA in PBS) at 37 1C for 1.5 h, and then incubated
with primary antibodies, antineuroﬁlament M (145kD) 1:1000,
from Millipore (AB1987), and synaptophysin 1:1000, from Synpatic
Systems (101 002), overnight at RT in 1% BSA and 0.25% Tx-100 in
PBS. Anti-rabbit Dylight 488 conjugated secondary antibody (Stra-
tech, 71–485–152) was applied on the sections together with α-
bungarotoxin-tetramethylrhodamine conjugate both at a 1:1000
dilution in PBS; 1% BSA and incubated for 2 h at room temperature
before washing and mounting. Images were captured on an Incell
2000 and innervated (yellow) or denervated (red) end-plates were
counted with a minimum of 1000 NMJs counted per animal.
Human patient ﬁbroblast assays
Oxidative stress assay
Fibroblasts were obtained from human controls (n¼3) and ALS
patients with I113T SOD1 mutations (n¼3) and sporadic ALS
patients (n¼2). Cells were plated at 2500 cells/well in a 96-well
plate in 200 ml minimal media (PAA E15–825) supplemented with
10% FCS gold (PAA A15–151), 2 mM glutamine (Lonza BE17–605E),
50 mg/ml uridine (Sigma U3003), 100X vitamins (Lonza 13–607C5 ml in 500 ml), 100X amino acids(Lonza BE13–114E 5 ml in
500 ml), sodium pyruvate (Lonza BE13–115E 5 ml in 500 ml), and
penicillin/streptomycin (Lonza Be16–603E 5 ml in 500 ml 5000 U/
ml). The cells were incubated at 37 1C/5% CO2 overnight. The
following day the media were removed and the cells were washed
with 200 ml 1XP BS. Phenol red-free DMEM/F12 media (Sigma
D6434) was added in the presence of 10% serum/2 mM Gln (++),
10% serum/0 mM Gln (+−), or 0% serum/0 mM Gln (−−). Cells were
incubated at 37 1C/5% CO2 for 5 h. A 50-ml volume containing
10 mM carboxy-H2DCFDA and 0.34 mM EthD1 in 1X PBS was added
for 1 h.
The plate was read at Ex485 nm/Em530 nm (carboxy-H2DCFDA
ﬂuorescence) and Ex530 nm/Em645 nm (EthD1, toxicity). To measure
cell number the plate was freeze-thawed and 50 ml of 1 mM EthD1
in PBS was added and the ﬂuorescence at Ex530 nm/Em645 nm
measured. Carboxy-H2DCFDA ﬂuorescence was normalised to live
cell number (total EthD1 signal after freeze/thaw – EthD1 signal
after assay) to compare between the different cell lines. Data were
analysed by one-way ANOVA with Bonferroni post tests using
GraphPad Prism
S[+]-Apomorphine assay
Cells were plated as above and the following day the media
were removed and replaced with media containing 3.7 or 0.41 mM
S[+]-apomorphine (Sigma, DO43) or 0.02% DMSO as a control.
The cells were incubated for 24 h at 37 1C/5% CO2, and the cells
were washed with 200 ml 1X PBS. DMEM/F12 (50 ml) media were
added in the presence of 10% serum/0 mM Gln (+−) and the cells
were incubated at 37 1C and 5% CO2 for 5 h. A 50-ml volume of
10 mM carboxy-H2DCFDA in 1X PBS was then added for 1 h and the
plate read at Ex485 nm/Em530 nm. To measure the cell number the
plate was freeze-thawed, 5 0ul of 2 mM EthD in PBS was added to
each well, and the ﬂuorescence read at Ex530 nm/Em645 nm.
At the two apomorphine concentrations tested, there was no
effect on cell number compared to the DMSO control; therefore
data were analysed by removing blank values from the test
carboxy-H2DCFDA ﬂuorescence values. The data were tested for
normality and analysed by one-way ANOVA using GraphPad Prism.
Pharmacokinetic analysis
Pharmacokinetic studies were performed by Pharmidex
(London, UK). All plasma, CSF, and brain samples were analysed
by LC/MS-MS using an Agilent 6410 triple quad LC/MS system to
quantify the amount of drug present using a spiked standard curve
in the corresponding matrix to the samples. All concentrations
were calculated with reference to the relevant standard curve. An
extraction buffer (EB) solution of acetonitrile with 0.1% formic acid
(Fisher Scientiﬁc, HPLC grade) and 500 ng/ml of propranolol as the
internal standard (IS) was used for in all extraction protocols. A 1-
ml volume of samples was run on a Phenomenex Synergi Hydro-RP
302.1 mm column on an Agilent G1312B HPLC with mobile
phases of methanol + 0.1% formic acid (A) and water + 0.1% formic
acid (B), run in a 0.5 ml gradient from 10% A to 95% A at a ﬂow rate
of 0.5 ml/min followed by mass spectrometry.
Pharmacokinetic modeling
A physiologically based pharmacokinetic (PBPK) model for
apomorphine was developed in the Simcyp mouse simulator
(v11.1) (Simcyp Limited, Shefﬁeld, UK). The following physico-
chemical data were used: LogP 3.5 (Supplementary Table 2),
MW 267.3, compound type monoprotic base (pKa 8.92). A plasma
protein binding fraction in mouse of 0.222 (unbound) and a blood:
plasma ratio of 1 as measured in humans was assumed [73]. The
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supplementary Table 4) was used to describe the elimination of the
compound. Using a ﬁxed value for clearance makes the assumption
that clearance is linear across the dose ranges studied. Distribution
was predicted using the method of Poulin and Theil as corrected by
Berezhkovskiy [74]. The measured brain:plasma (Kp) value (2.1) was
used in the model and the Kp values for other tissues were manually
adjusted to give a reasonable ﬁt of the observed data. To model
exposure after oral dosing a ﬁrst-order absorption model was used
(Fa¼1; Ka¼1.5) After showing that the model could capture the
observed plasma and brain levels after iv and oral dosing, simulations
were performed to predict plasma and brain concentrations follow-
ing a 2.5 and 5 mg/kg subcutaneous dose. To do this an extravascular
dose was administered such that the AUC was 2.5 or 5 times higher
than that at the 1 mg/kg intravenous dose. This assumes that the
fraction absorbed following subcutaneous dosing was 1 as has been
observed in studies in humans [75]. Simulations were performed
with a range of Ka values to give similar Tmax values to those seen
following subcutaneous dosing in humans (8–16 min) [76].
Pharmacodynamic analysis
Male C57BL/6J mice at 6–8 weeks of age were injected with
10 ml/kg of vehicle (0.1% DMSO in water), or S[+]-apomorphine at
0.25 or 0.5 mg/ml subcutaneously to give ﬁnal doses of 2.5 and
5 mg/kg. Tissue was collected from groups of three mice for each
dose at 6, 24, 48, and 84 h into RNA later. RNA was isolated using
Qiagen RNeasy mini kit and Q-RTPCR performed on HO-1 and
NQO-1 genes as described previously.
Statistical analysis
For the Spectrum library screen, each 384-well plate contained
32 wells incubated with vehicle only (0.1% DMSO in media). The
average ﬂuorescence reading and standard deviation of these
wells was calculated on a plate by plate basis. Hits were classiﬁed
as having a GFP ﬂuorescence value greater than the vehicle
average plus three standard deviations. Toxicity was deﬁned in
the same way (i.e., EthD1 ﬂuorescence value greater than the
vehicle average plus three standard deviations).Competing Interests
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